Study on the pathogenesis of infantile hemangioma and the related mechanism of propranolol treatment

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100053571

Enrollment

Unknown

Registered

2021-11-24

Start date

2022-01-01

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infantile Hemangioma

Interventions

Experimental group:Oral propranolol

Eligibility

Sex/Gender

All

Age

No minimum to 1 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for infantile hemangioma in the 2019 edition of the Guidelines for the Treatment of Hemangioma and Vascular Malformation. 2. Age selection is in the proliferative period < 6 months, and the gender is not limited. 3. In line with the indications of propranolol systemic medication. 4. Obtain the consent of the child's guardian.

Exclusion criteria

Exclusion criteria: 1. The tumor has ulcers, infection, etc. 2. There are contraindications to oral propranolol. 3. According to the judgment of the researcher, the guardian is untrustworthy or has poor compliance.

Design outcomes

Primary

Measure	Time frame
tumor size;colour;pathology;	—

Countries

China

Contacts

Public ContactWang Hua

Children's Hospital of Chongqing Medical University

huawang63@hotmail.com+86 15123380348

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026